Get in touch
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact usMyriad Associates is proud to announce that 4 of our clients who applied for the Disruptive Technologies Innovation Fund were all approved on Monday 10th December.
With a combined grant value of €14.9m, this will provide a major boost to the MedTech and Cellular Therapy communities in Galway.
The first 27 projects from Ireland’s €500m Disruptive Technologies Innovation Fund (DTIF) were announced this week and will receive a combined €75m in support.
Marc Greatrex, Director of Grants at Myriad Associates commented the success of these applications was a testament to the strength of concepts with the passion, drive and commitment of the SMEs in Galway “We are absolutely thrilled and humbled to have 4 out of 4 applications accepted by the DTIF, we were always hopeful and glad we could help these consortia secure the funding. The technologies they're developing will have a major impact for patients and on the Irish National Strategic Outcomes in the coming years”
The full list of approved projects can be accessed here. They include a scheme to help communities generate their own electricity, new treatments for sepsis, a support system for coastal flooding and advanced 3D printing of medical implants.
This blog provides a comprehensive guide to Innovate UK funding and support for businesses and startups in the UK, with a focus on unlocking innovation and driving growth through emerging technologies and research and development.
Innovate UK is now looking to invest up to £25 million in game-changing and commercially viable R&D innovation that can significantly impact the UK economy.
UK registered micro and small businesses in the creative industries sector, can apply for funding up to £50,000 with a package of support to grow their business.
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact us